The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.

doi:10.1007/s10549-009-0595-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.

Breast cancer research and treatment - 1 Jun 2010

Jakubowska Anna, Rozkrut Dominik, Antoniou Antonis, Hamann Ute, Lubinski Jan

Abstract excerpt

Integrins containing the beta(3) subunit are key players in tumor growth and metastasis. A functional Leu33Pro polymorphism (rs5918) in the beta(3) subunit of the integrin gene (ITGB3) has previously been suggested to act as a modifier of ovarian cancer risk in Polish BRCA1 mutation carriers. To investigate the association further, we genotyped 9,998 BRCA1 and 5,544 BRCA2 mutation carriers from 34 studies from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Heterozygote

Share to Integrin beta3

Share to Ovarian Neoplasms

Share to Proportional Hazards Models

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 19876733
DOI: 10.1007/s10549-009-0595-7
PMCID: PMC3077711

Genes

BRCA1
BRCA2
ITGB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.PMID 19876733Read ↗

No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype.Semantic proximity Read ↗

Integrin beta3 Leu33Pro homozygosity and risk of cancer.Semantic proximity Read ↗

Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.Semantic proximity Read ↗

Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.Semantic proximity Read ↗

Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk.Semantic proximity Read ↗

Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population.Semantic proximity Read ↗

Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.Semantic proximity Read ↗

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients.Semantic proximity Read ↗

Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab.Semantic proximity Read ↗

The 825C>T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer.Semantic proximity Read ↗

Integrin genes and susceptibility to human melanoma.Semantic proximity Read ↗

Role of GSK3β in breast cancer susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.